BIOMARKER EXPLAINER
pTau-217 Blood Test
This page explains what plasma pTau-217 is, why it matters when changes in memory, focus, or day-to-day function raise concern, and how results can help determine what to do next within clinical context.
What This Test Measures
pTau-217 is a phosphorylated form of tau protein measured in blood plasma. Elevated pTau-217 levels are associated with Alzheimer's-related brain pathology and help clinicians estimate whether amyloid/tau changes are likely present.
In clinical workflows, pTau-217 is typically used as part of a broader evaluation, not as a stand-alone diagnosis.
In Plain Language
What It Can Tell You
The test helps you understand whether Alzheimer's-type biomarker changes may be part of what is happening.
What It Cannot Do Alone
It does not replace a full medical assessment, cognitive history, or clinician judgment.
How It's Usually Used
It helps guide next steps, such as additional evaluation, imaging, treatment discussions, or specialist follow-up.
CLIA Laboratory Processing
- Specimen type: EDTA plasma collected through standard blood draw procedures
- Method: high-sensitivity immunoassay performed by a CLIA-certified laboratory
- Expected turnaround: typically several business days after sample receipt
- Result format: reports may use negative, intermediate, and positive interpretation bands
- Status: laboratory developed test (LDT), not FDA-cleared or FDA-approved
Collection instructions, specimen handling requirements, and interpretation thresholds may be updated over time. Patients and providers should rely on the current ordering materials and the final issued laboratory report.
Important Note
Test details can change over time. Clinical decisions should rely on the ordering clinician and the most current report documentation issued with the test.
Ready to Move Forward?
If you or someone you love is noticing changes in memory, focus, or day-to-day function, or family history is raising concern, get the answers you need and take action on what you learn.